



MAYNE PHARMA LAUNCHES AMIODARONE TABLETS 100MG IN THE UNITED STATES

13 January 2017, Adelaide Australia: Mayne Pharma Group Limited (ASX: MYX) is pleased to announce the launch of amiodarone tablets, 100mg in the United States. Amiodarone is a generic alternative to Pacerone® tablets, indicated for life-threatening recurrent ventricular arrhythmia. Mayne Pharma already markets a 400mg strength of this product.

Mayne Pharma's CEO, Mr Scott Richards, said "The amiodarone launch reinforces Mayne Pharma's commitment to expanding its on-market portfolio by introducing a steady stream of new products. Today, Mayne Pharma now directly markets more than 50 products and we have a growing pipeline of more than 40 generic and branded drug products targeting US markets with IMS sales greater than US\$6 billion."

According to IMS Health, US brand and generic sales of amiodarone tablets, 100mg, were approximately US\$23 million for the 12 months ending 30 November 2016.

For further information contact:

Scott Richards +61 8 8209 2410

Lisa Pendlebury +61 419 548 434, lisa.pendlebury@maynepharma.com

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on applying its drug delivery expertise to commercialise branded and generic pharmaceuticals, providing patients with access to better and more affordable medicines. Mayne Pharma also provides contract development and manufacturing services to more than 100 clients worldwide.

Mayne Pharma has a 30-year track record of innovation and success in developing new oral drug delivery systems and these technologies have been successfully commercialised in numerous products that have been marketed around the world.

Mayne Pharma has two product development and manufacturing facilities based in Salisbury, Australia and Greenville, USA with expertise in the formulation of complex oral dose forms including highly potent compounds, controlled substances, modified-release products and inherently unstable compounds.

Pacerone® is a registered trademark in the US of Upsher-Smith Laboratories, Inc.

